Cargando…

3D bioprinted breast tumor-stroma models for pre-clinical drug testing

The use of three-dimensional (3D) bioprinting has been proposed for the reproducible production of 3D disease models that can be used for high-throughput drug testing and personalized medicine. However, most such models insufficiently reproduce the features and environment of real tumors. We report...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Callejo, Patricia, Vázquez-Aristizabal, Paula, García-Astrain, Clara, Jimenez de Aberasturi, Dorleta, Henriksen-Lacey, Malou, Izeta, Ander, Liz-Marzán, Luis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622882/
https://www.ncbi.nlm.nih.gov/pubmed/37928251
http://dx.doi.org/10.1016/j.mtbio.2023.100826
_version_ 1785130639761080320
author González-Callejo, Patricia
Vázquez-Aristizabal, Paula
García-Astrain, Clara
Jimenez de Aberasturi, Dorleta
Henriksen-Lacey, Malou
Izeta, Ander
Liz-Marzán, Luis M.
author_facet González-Callejo, Patricia
Vázquez-Aristizabal, Paula
García-Astrain, Clara
Jimenez de Aberasturi, Dorleta
Henriksen-Lacey, Malou
Izeta, Ander
Liz-Marzán, Luis M.
author_sort González-Callejo, Patricia
collection PubMed
description The use of three-dimensional (3D) bioprinting has been proposed for the reproducible production of 3D disease models that can be used for high-throughput drug testing and personalized medicine. However, most such models insufficiently reproduce the features and environment of real tumors. We report the development of bioprinted in vitro 3D tumor models for breast cancer, which physically and biochemically mimic important aspects of the native tumor microenvironment, designed to study therapeutic efficacy. By combining a mix of breast decellularized extracellular matrix and methacrylated hyaluronic acid with tumor-derived cells and non-cancerous stromal cells of biological relevance to breast cancer, we show that biological signaling pathways involved in tumor progression can be replicated in a carefully designed tumor-stroma environment. Finally, we demonstrate proof-of-concept application of these models as a reproducible platform for investigating therapeutic responses to commonly used chemotherapeutic agents.
format Online
Article
Text
id pubmed-10622882
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106228822023-11-04 3D bioprinted breast tumor-stroma models for pre-clinical drug testing González-Callejo, Patricia Vázquez-Aristizabal, Paula García-Astrain, Clara Jimenez de Aberasturi, Dorleta Henriksen-Lacey, Malou Izeta, Ander Liz-Marzán, Luis M. Mater Today Bio Full Length Article The use of three-dimensional (3D) bioprinting has been proposed for the reproducible production of 3D disease models that can be used for high-throughput drug testing and personalized medicine. However, most such models insufficiently reproduce the features and environment of real tumors. We report the development of bioprinted in vitro 3D tumor models for breast cancer, which physically and biochemically mimic important aspects of the native tumor microenvironment, designed to study therapeutic efficacy. By combining a mix of breast decellularized extracellular matrix and methacrylated hyaluronic acid with tumor-derived cells and non-cancerous stromal cells of biological relevance to breast cancer, we show that biological signaling pathways involved in tumor progression can be replicated in a carefully designed tumor-stroma environment. Finally, we demonstrate proof-of-concept application of these models as a reproducible platform for investigating therapeutic responses to commonly used chemotherapeutic agents. Elsevier 2023-09-30 /pmc/articles/PMC10622882/ /pubmed/37928251 http://dx.doi.org/10.1016/j.mtbio.2023.100826 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
González-Callejo, Patricia
Vázquez-Aristizabal, Paula
García-Astrain, Clara
Jimenez de Aberasturi, Dorleta
Henriksen-Lacey, Malou
Izeta, Ander
Liz-Marzán, Luis M.
3D bioprinted breast tumor-stroma models for pre-clinical drug testing
title 3D bioprinted breast tumor-stroma models for pre-clinical drug testing
title_full 3D bioprinted breast tumor-stroma models for pre-clinical drug testing
title_fullStr 3D bioprinted breast tumor-stroma models for pre-clinical drug testing
title_full_unstemmed 3D bioprinted breast tumor-stroma models for pre-clinical drug testing
title_short 3D bioprinted breast tumor-stroma models for pre-clinical drug testing
title_sort 3d bioprinted breast tumor-stroma models for pre-clinical drug testing
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622882/
https://www.ncbi.nlm.nih.gov/pubmed/37928251
http://dx.doi.org/10.1016/j.mtbio.2023.100826
work_keys_str_mv AT gonzalezcallejopatricia 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting
AT vazquezaristizabalpaula 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting
AT garciaastrainclara 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting
AT jimenezdeaberasturidorleta 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting
AT henriksenlaceymalou 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting
AT izetaander 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting
AT lizmarzanluism 3dbioprintedbreasttumorstromamodelsforpreclinicaldrugtesting